clopidogrel

Clopidogrel (SR-25990C), a P2Y12 receptor antagonist, decreases platelet aggregation.

Clopidogrel hydrogen sulfate ((S)-(+)-Clopidogrel bisulfate) , a selective, high-affinity P2Y12 receptor antagonist, suppressess fibrinogen binding to platelets and platelet adhesion and aggregation.

(±) Clopidogrel hydrogen sulfate (Iscover) , an antiplatelet agent pharmacologically and structurally analogous to ticlopidine, is used to inhibit blood clots in various conditions such as cerebrovascular disease, peripheral vascular disease, and coronary artery disease.

Clopidogrel HCl is the salt form of Clopidogrel (free base), an inhibitor of ADP-induced platelet aggregation acting by direct inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex.

2-oxo Clopidogrel is an intermediary metabolite of clopidogrel . Clopidogrel is a prodrug that is converted to its active metabolite via two sequential oxidative steps. The first step leads to formation of 2-oxo clopidogrel, followed by conversion to the active metabolite, which binds specifically and irreversibly to the platelet P2Y12 purinergic receptor, inhibiting ADP-mediated platelet activation and aggregation.

Clopidogrel thiolactone (2-oxoclopidogrel) is a potent P2Y12 receptor inhibitor and a potent antiplatelet aggregation compound.Clopidogrel thiolactone is the active metabolic intermediate resulting from the first oxidative activation of Clopidogrel.

Clopidogrel Related Compound C is a useful organic compound for research related to life sciences. The catalog number is T126236 and the CAS number is 120202-71-3.

Clopidogrel is an antithrombic compound whose active metabolite is a selective, irreversible antagonist of the platelet purinergic P2Y12 receptor (IC50 = 100 nM). Clopidogrel inhibits ADP-induced platelet aggregation ex vivo and functions as a prodrug whereupon biotransformation to its active thiol metabolite via CYP2C19 in the liver enables its anti-aggregating activity. An estimated 15% of administered clopidogrel is metabolized by CYP2C19 to the thiol metabolite. Clopidogrel carboxylic acid is a major inactive metabolite of clopidogrel. Most (85%) of circulating clopidogrel is hydrolyzed by esterases to this carboxylic acid form. This inactive metabolite can be used as a reference standard for quantitative analysis of clopidogrel metabolism.

Clopidogrel Related Compound A is a useful organic compound for research related to life sciences. The catalog number is T125853 and the CAS number is 144457-28-3.

Clopidogrel is an antithrombic compound whose active metabolite is a selective, irreversible antagonist of the platelet purinergic P2Y12 receptor (IC50 = 100 nM). Clopidogrel inhibits ADP-induced platelet aggregation ex vivo and functions as a prodrug whereupon biotransformation to its active metabolite via CYP2C19 in the liver enables its anti-aggregating activity. Marketed under the name Plavix , clopidogrel in combination with aspirin has been shown to be beneficial in the prevention of vascular ischemic events for patients without deficiencies in CYP2C19-related metabolism.

rac-Clopidogrel-d4 Carboxylic Acid is a deuterated compound of rac-Clopidogrel Carboxylic Acid. rac-Clopidogrel Carboxylic Acid has a CAS number of 113665-84-2. Clopidogrel, a P2Y12 receptor antagonist, decreases platelet aggregation.

rac-Clopidogrel-d4 Hydrogen Sulfate is a deuterated compound of rac-Clopidogrel Hydrogen Sulfate. rac-Clopidogrel Hydrogen Sulfate has a CAS number of 135046-48-9. Clopidogrel, an antiplatelet agent pharmacologically and structurally analogous to ticlopidine, is used to inhibit blood clots in various conditions such as cerebrovascular disease, peripheral vascular disease, and coronary artery disease.

Clopidogrel Related Compound B is a useful organic compound for research related to life sciences. The catalog number is T125846 and the CAS number is 144750-52-7.

cis-Clopidogrel-MP-13C-d3 Derivative is the 13C and deuterated compound of cis-Clopidogrel-MP Derivative.

cis-Clopidogrel-MP derivative, also known as Clopidogrel-MP-AM, is a 3’-methoxyacetophenone derivative of Clopidogrel active metabolite. This compound is an orally-active platelet inhibitor specifically targeting the P2Y12 receptor.

Ticagrelor metabolite M5 (T437700) is a metabolite of Ticagrelor, the first reversible oral antagonist of P2Y12 receptor. Compared to Clopidogrel, Ticagrelor has faster and more consistent inhibition on ADP-receptors. Ticagrelor is used in the treatment of acute coronary syndromes (ACS).

Atorvastatin, an orally active HMG-CoA reductase inhibitor, effectively lowers blood lipids by activating liver cytochrome p450 to accelerate metabolism. Atorvastatin inhibits the proliferation and invasion of human SV-SMC cells with IC50 values of 0.39 μM and 2.39 μM, respectively. [Atorvastatin] combined with clopidogrel may lead to increased thrombotic events in patients.

Ticagrelor-d7 is a deuterated compound of Ticagrelor. Ticagrelor has a CAS number of 274693-27-5. Ticagrelor, produced by AstraZeneca, is an inhibitor of platelet aggregation. Unlike clopidogrel, ticagrelor is not a prodrug required metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010, and by the US FDA on July 20, 2011. Its trade names are Brilinta (US), Brilique(EU) and Possia(EU).

ACT-281959, a prodrug of ACT-246475, is a novel potent and selective P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel. ACT-281959 showed antithrombotic efficacy after oral administration in the rat ferric chloride model. ACT-281959 entered clinical studies in healthy volunteers.

Ticagrelor (AR-C 126532XX), produced by AstraZeneca, is an inhibitor of platelet aggregation. Unlike clopidogrel, ticagrelor is not a prodrug required metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010, and by the US FDA on July 20, 2011. Its trade names are Brilinta (US), Brilique(EU) and Possia(EU).

Bivalirudin TFA, a synthetic 20-residue peptide, serves as a reversible inhibitor of thrombin. Its IC50 value highlights its target specificity in vitro, where, combined with Eptifibatide (8 mg/mL) at a low concentration (70 ng/mL), it significantly reduces platelet aggregation induced by thrombin (0.2 U/mL) by approximately 90% [1]. The compound demonstrates no effect on thrombin generation assay (TGA) parameters up to 10 μmol/L [2]. Additionally, it facilitates the binding of MPO to BAEC, leading to functional alterations such as increased NO consumption and enhanced MPO-mediated redox modifications [3]. In vivo studies reveal its efficacy in preventing the rise of antiheparin/PF4 antibody IgG levels in rats, with significant findings from the toxicokinetic assessment signaling its safety profile at tested doses, although higher doses resulted in fatalities [4][5]. In clinical trials, its antithrombotic effects were explored, comparing it with alternatives like Ticagrelor and Clopidogrel in a Phase 4 study.